We are pleased to introduce the addition of a new product, itis-for inflammation. Comprised of bromelain, boswelia serrata, cats claw, devils claw, feverfew tanacetum, tumeric (curcumin), and tart cherry fruit, itis is formulated to relieve the inflammation specific to Lyme disease, chronic fatigue syndrome (CFS), fibromyalgia, arthritis, and inflammatory conditions of the nervous system, such as multiple sclerosis (MS). Over the next few weeks, we will take a closer look at each of these ingredients in turn, beginning with bromelain.
Bromelain is a proteolytic enzyme that inhibits the migration of white blood cells to sites of injury or infection, and removes the chemical receptor necessary for inflammation to occur. In a study of 77 individuals with knee pain, daily doses of 200-400mg effectively reduced pain and increased reported perceptions of well-being. In addition, Bromelain acts as an immunomodulator against tumor cells, via the production of anti-inflammatory cytokines–chemical signalers–such as tumor necrosis factor-a (TNF-alpha) and interleukin II.
In the next post, we will examine boswellia serrata’s ability to reduce painful swelling and increase the range of motion in patients with inflammatory conditions.
In Principles and Applications of Ozone Therapy (2011), Dr. Frank Shallenberger tells of his introduction to ozone therapy via the work of his predecessor, Dr. Charles Farr. In the 1980s, Dr. Farr began treating patients with Auto Immune Disease Syndrome (AIDS)—caused by the accumulation of molecules called oxidants—by injecting hydrogen peroxide, a powerful oxidant, directly into their veins. Dr. Farr’s success at alleviating symptoms such as fatigue, insomnia, brain fog, joint and muscle pain, and muscle weakness suggested that “the reason people get sick and diseased as they get older might have something to do with how they utilize and process oxygen” (Shallenberger, 2011).
The following Q & A is intended provide an introduction to ozone, and the various ozone therapies our clinic provides:
Q: What is ozone?
A: Consisting of three oxygen (O2) atoms that share a common electron, ozone (O3) is a naturally occurring molecule—called an oxidant—in the earth’s atmosphere.
Q: What is ozone therapy?
A: Working in a manner similar to vaccines that promote the production of viral antibodies, ozone therapy stimulates the formation of oxidants in the blood, essentially training the body to utilize them efficiently.
Q: How is ozone administered?
A: There are three administration techniques for ozone therapy. The first, called an Ozone Sauna, involves the patient entering a hyperbaric chamber into which heated ozone is pumped. The heat causes the patient to perspire, while the ozone promotes the formation of oxidants in the blood that the body must then dispose of. When someone says they are “sweating it out,” this is the technique to which they are referring.
The second option, called minor-Auto-Hemo-therapy (mAH), involves the blood being drawn out of the body, mixed with ozone, and then injected directly into the treatment site, while the third option administers blood-ozone intravenously, and is referred to as Major-Auto-Hemo-therapy (MAH).
Q: What conditions can ozone therapy treat?
A: Here at Restorative Health Clinic, we offer ozone therapy for patients with Lyme disease, chronic fatigue syndrome (CFS), and the chronic infections typically related to such illnesses. Essentially, any condition that impairs the body’s natural immunity can be treated with ozone, as it stimulates auto-immune defense mechanisms, necessary for tissue and cellular repair.
Q: How do I know if ozone therapy is right for me?
A: Consult your physician regarding the potential benefits and appropriate administration method for your particular condition. Dr. Vosloo and Dr. Hatlestad look forward to providing their guidance to anyone looking to improve their health and vitality.
If you would like to schedule an appointment, please give us a call at 503.747.2021.
Platelet Rich Plasma Therapy, once reserved for elite athletes, continues to gain popularity among the general public. Research
is also overwhelmingly positive in the treatment of numerous musculoskeletal complaints. The following article shows the potential
for PRP to improve knee osteoarthritis also known as degenerative joint disease. This is especially exciting because medical
treatment for osteoarthritis is mostly inadequate. If you or someone you know is suffering from knee pain, or other joint pains,
PRP may be an effective treatment option for you. If you have any questions, you can contact me either via email or call the clinic.
Platelet-rich plasma (prp) treatment shows potential for knee osteoarthritis
Date: February 12, 2013
Source: Hospital for Special Surgery
Summary: A new study has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis. The treatment improved pain and function, and in up to 73% of patients, appeared to delay the progression of osteoarthritis.
A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis. The treatment improved pain and function, and in up to 73% of patients, appeared to delay the progression of osteoarthritis, which is a progressive disease. The study appears online, ahead of print, in the Clinical Journal of Sports Medicine.
“This is a very positive study,” said Brian Halpern, M.D., chief of the Primary Care Sports Medicine Service at Hospital for Special Surgery, New York City, and lead author of the study.
Several treatments for osteoarthritis exist, including exercise, weight control, bracing, nonsteroidal anti-inflammatories, Tylenol, cortisone shots and viscosupplementation, a procedure that involves injecting a gel-like substance into the knee to supplement the natural lubricant in the joint. A new treatment that is being studied by a small number of doctors is PRP injections. PRP, which is produced from a patient’s own blood, delivers a high concentration of growth factors to arthritic cartilage that can potentially enhance healing.
“You take a person’s blood, you spin it down, you concentrate the platelets, and you inject a person’s knee with their own platelets in a concentrated form,” said Dr. Halpern. “This then activates growth factors and stem cells to help repair the tissue, if possible, calm osteoarthritic symptoms and decrease inflammation.”
In the new study, researchers at Hospital for Special Surgery enrolled patients with early osteoarthritis, gave them each an injection of PRP (6-mL), and then monitored them for one year. Fifteen patients underwent clinical assessments at baseline, one week, and one, three, six, and 12 months. At these time points, clinicians used validated tools to assess overall knee pain, stiffness and function, as well as a patient’s ability to perform various activities of daily living. At baseline and then one year after the PRP injection, physicians also evaluated the knee cartilage with magnetic resonance imaging (MRI), something that has not previously been done by researchers in other PRP studies. The radiologists reading the MRIs did not know whether the examination was performed before or after the PRP treatment.
“The problem with a lot of the PRP studies is that most people have just used subjective outcome instruments, such as pain and function scores,” said Hollis Potter, M.D., chief of the Division of Magnetic Resonance Imaging at Hospital for Special Surgery, another author of the study. “But even when patients are blinded, they know there has been some treatment, so there is often some bias interjected into those types of studies. When you add MRI assessment, it shows you the status of the disease at that time, regardless of whether the patient is symptomatic or asymptomatic or they have good or poor function in the knee. You find out what the cartilage actually looks like. We can noninvasively assess the matrix or the building blocks of cartilage.”
While previous studies have shown that patients with osteoarthritis can lose roughly five percent of knee cartilage per year, the HSS investigators found that a large majority of patients in their study had no further cartilage loss. “The knee can be divided into three compartments, the medial compartment, the lateral compartment and the patellofemoral compartment,” said Dr. Halpern. “If we look at these compartments individually, which we did, in at least 73% of these cases, there was no progression of arthritis per compartment at one year. That is very significant, because longitudinal studies suggest a four to six percent progression of arthritis at one year.”
Treatment with PRP was also useful in improving pain, stiffness and function. The investigators found that pain, measured by a standard test called the Western Ontario and McMaster Universities Arthritis Index, significantly improved with a reduction of 41.7% at six months and 55.9% at one year. On a pain scale commonly used by clinicians called the Visual Analog Scale, pain was reduced by 56.2% at six months and 58.9% at one year. Functional scores improved by 24.3% at one year. Activity of Daily Living Scores also showed a significant increase at both six months (46.8%) and one year (55.7%).
“We are entering into an era of biologic treatment, which is incredibly ideal, where you can use your own cells to try to help repair your other cells, rather than using a substance that is artificial,” Dr. Halpern said. “The downside is next to zero and the upside is huge.” Dr. Halpern pointed out, however, that the study is a small case series and PRP needs to be pitted against a traditionally treated group in a randomized, controlled trial.
Osteoarthritis, which causes pain and joint stiffness, impacts over 27 million Americans and is a leading cause of disability. According to statistics from the Centers for Disease Control and Prevention, overall osteoarthritis affects 13.9% of adults aged 25 and older and 33.6% of those older than 65. The disease is characterized by degeneration of cartilage and its underlying bone within a joint as well as bony overgrowth. Disease onset is gradual and usually begins after the age of 40.
Other HSS investigators involved in the study include Salma Chaudhury, M.D., Ph.D, Scott Rodeo, M.D., Catherine Hayter, MBBS, Eric Bogner, M.D., and Joseph Nguyen, MPH.
The above story is based on materials provided by Hospital for Special Surgery.Note: Materials may be edited for content and length.
- Brian Halpern, Salma Chaudhury, Scott A. Rodeo, Catherine Hayter, Eric Bogner, Hollis G. Potter, Joseph Nguyen. Clinical and MRI Outcomes After Platelet-Rich Plasma Treatment for Knee Osteoarthritis. Clinical Journal of Sport Medicine, 2012; 1 DOI: 10.1097/JSM.0b013e31827c3846
A colleague and someone that I learned directly from, Jeff Patterson DO, co-authored a recent blinded trial of dextrose prolotherapy vs. placebo injection or exercise therapy. The results suggested that prolotherapy is an effective solution for knee osteoarthritis with reductions in pain and stiffness and an increase in range of motion and function. This is not new, but more confirmatory results of the effectiveness of prolotherapy for numerous types of joint pain and musculoskeletal complaints.
June 04, 2013
Dextrose Prolotherapy Can Improve Knee Osteoarthritis
(HealthDay News) – For adults with knee osteoarthritis, dextrose prolotherapy is associated with greater improvements in pain, function, and stiffness compared with saline injections or at-home exercise, according to a study published in the May/June issue of the Annals of Family Medicine.
David Rabago, MD, of the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues conducted a three-arm blinded, randomized controlled trial involving 90 adults with ≥3 months of painful knee osteoarthritis. Participants were randomized to receive blinded injection (dextrose prolotherapy or saline) or at-home exercise. Injections were provided at weeks one, five, and nine, with additional treatments at weeks 13 and 17, as needed. An exercise manual and in-person instruction were provided to exercise participants.
The researchers found that all groups reported an improvement in composite Western Ontario McMaster University Osteoarthritis Index (WOMAC) scores from baseline to 52 weeks. The improvement in WOMAC scores at 52 weeks was significantly more for the dextrose prolotherapy group compared with the saline or exercise groups, after adjustment for age, sex, and body mass index. In the prolotherapy group, the individual knee pain scores also improved more. High satisfaction was noted with prolotherapy and there were no adverse events reported.
“Prolotherapy resulted in clinically meaningful sustained improvement of pain, function, and stiffness scores for knee osteoarthritis compared with blinded saline injections and at-home exercises,” the authors write.
The Abstract From the Recent Study:
Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial
- David Rabago, MD1⇑, Jeffrey J. Patterson, DO1, Marlon Mundt, PhD1,Richard Kijowski, MD2, Jessica Grettie, BS1, Neil A. Segal, MD, MS3 andAleksandra Zgierska, MD, PhD1
Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Departments of Orthopaedics & Rehabilitation, Epidemiology, and Radiology, The University of Iowa, Iowa City, Iowa
David Rabago, MD, Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, firstname.lastname@example.org
Knee osteoarthritis is a common, debilitating chronic disease. Prolotherapy is an injection therapy for chronic musculoskeletal pain. We conducted a 3-arm, blinded (injector, assessor, injection group participants), randomized controlled trial to assess the efficacy of prolotherapy for knee osteoarthritis.
Ninety adults with at least 3 months of painful knee osteoarthritis were randomized to blinded injection (dextrose prolotherapy or saline) or at-home exercise. Extra- and intra-articular injections were done at 1, 5, and 9 weeks with as-needed additional treatments at weeks 13 and 17. Exercise participants received an exercise manual and in-person instruction. Outcome measures included a composite score on the Western Ontario McMaster University Osteoarthritis Index (WOMAC; 100 points); knee pain scale (KPS; individual knee), post-procedure opioid medication use, and participant satisfaction. Intention-to-treat analysis using analysis of variance was used.
No baseline differences existed between groups. All groups reported improved composite WOMAC scores compared with baseline status (P <.01) at 52 weeks. Adjusted for sex, age, and body mass index, WOMAC scores for patients receiving dextrose prolotherapy improved more (P <.05) at 52 weeks than did scores for patients receiving saline and exercise (score change: 15.3 ± 3.5 vs 7.6 ± 3.4, and 8.2 ± 3.3 points, respectively) and exceeded the WOMAC-based minimal clinically important difference. Individual knee pain scores also improved more in the prolotherapy group (P = .05). Use of prescribed postprocedure opioid medication resulted in rapid diminution of injection-related pain. Satisfaction with prolotherapy was high. There were no adverse events.
Prolotherapy resulted in clinically meaningful sustained improvement of pain, function, and stiffness scores for knee osteoarthritis compared with blinded saline injections and at-home exercises.
For full text of this research study: http://www.annfammed.org/content/11/3/229.full
Dr Glen Jarosz is a skilled practitioner of prolotherapy as well as numerous other regenerative injection therapies. Please contact him for a free consultation to see if you may benefit from prolotherapy.